Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence

Developmental Neuroscience

Volumn 37, Issue 1, 2015, Pages 43-55

  Farrelly, Lorna ^a   Föcking, Melanie ^a   Piontkewitz, Yael ^d   Dicker, Patrick ^b   English, Jane ^a   Wynne, Kieran ^c   Cannon, Mary ^a   Cagney, Gerard ^c   Cotter, David R ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Maternal immune activation; Myelin; Polyinosinic:polycytidylic acid; Proteomics; Risperidone; Schizophrenia

Indexed keywords

MYELIN; POLYINOSINIC POLYCYTIDYLIC ACID; RISPERIDONE; SODIUM CHLORIDE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; GLUCONEOGENESIS; GLYCOLYSIS; IMMUNITY; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; MATERNAL IMMUNE ACTIVATION; MYELINATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN METABOLISM; RAT; RIBOSOME; RISK FACTOR; SCHIZOPHRENIA; WESTERN BLOTTING; AGING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MYELIN SHEATH; PATHOLOGY; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE; WISTAR RAT;

AGING; ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; MALE; MYELIN SHEATH; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS, WISTAR; RISPERIDONE; SCHIZOPHRENIA;

EID: 84923578877     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000368305     Document Type: Article

References (75)

1. Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32: 200-202.
2. Brown AS, et al: Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-780.
3. Cannon M, et al: Prenatal exposure to the 1957 influenza epidemic and adult schizophrenia: a follow-up study. Br J Psychiatry 1996; 168: 368-371.
4. Carter CS, Bullmore ET, Harrison P: Is there a flame in the brain in psychosis? Biol Psychiatry 2014; 75: 258-259.
5. Singh B, Chaudhuri TK: Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res 2014; 216: 277-285.
6. English JA, et al: The neuroproteomics of schizophrenia. Biol Psychiatry 2011; 69: 163-172.
7. Focking M, et al: Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry 2011; 68: 477-488.
8. Pennington K, et al: Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
9. Perlstein WM, et al: Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 2001; 158: 1105-1113.
10. English JA, et al: 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9: 3368-3382.
11. Meyer U: Prenatal poly(I:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307-315.
12. Meyer U: Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 20-34.
13. Meyer U, Schwarz MJ, Muller N: Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132: 96-110.
14. Deng MY, et al: Frontal-subcortical protein expression following prenatal exposure to maternal inflammation. PloS One 2011; 6:e16638.
15. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261-280.
16. Cotter D, et al: Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Schizophr Res 1995; 16: 233-241.
17. Fatemi SH, et al: Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 2005; 57: 91-99.
18. Meyer U, Feldon J: To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 2012; 62: 1308-1321.
19. Piontkewitz Y, Assaf Y, Weiner I: Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry 2009; 66: 1038-1046.
20. Piontkewitz Y, Arad M, Weiner I: Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2011; 37: 1257-1269.
21. Piontkewitz Y, et al: Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 2012; 26: 353-363.
22. Cotter DR, Pariante CM, Everall IP: Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001; 55: 585-595.
23. Hakak Y, et al: Genome-wide expression analysis reveals dysregulation of myelinationrelated genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
24. Tkachev D, et al: Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
25. Rinholm JE, et al: Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci 2011; 31: 538-548.
26. Prabakaran S, et al: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-697, 643.
27. Martins-de-Souza D, et al: The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxidants Redox Signaling 2011; 15: 2067-2079.
28. Martins-de-Souza D, et al: Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 2010; 44: 1176-1189.
29. Giulivi C, et al: Gestational exposure to a viral mimetic poly(I:C) results in long-lasting changes in mitochondrial function by leucocytes in the adult offspring. Mediat Inflamm 2013; 2013: 609602.
30. Grunert T, et al: A comparative proteome analysis links tyrosine kinase 2 (Tyk2) to the regulation of cellular glucose and lipid metabolism in response to poly(I:C). J Proteom 2011; 74: 2866-2880.
31. Fatemi SH, et al: Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr Res 2009; 112: 46-53.
32. Makinodan M, et al: Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res 2008; 86: 2190-2200.
33. Jurado RL: Iron, infections, and anemia of inflammation. Clin Infect Dis 1997; 25: 888-895.
34. Todorich B, et al: Oligodendrocytes and myelination: the role of iron. Glia 2009; 57: 467-478.
35. Wang HD, et al: Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004; 29: 1230-1238.
36. Xiao L, et al: Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008; 13: 697-708.
37. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995; 9: 726-735.
38. MacDowell KS, et al: Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol 2013; 16: 121-135.
39. Sheean ME, et al: Activation of MAPK overrides the termination of myelin growth and replaces Nrg1/ErbB3 signals during Schwann cell development and myelination. Genes Dev 2014; 28: 290-303.
40. Ishii A, Furusho M, Bansal R: Sustained activation of ERK1/2 MAPK in oligodendrocytes and Schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion. J Neurosci 2013; 33: 175-186.
41. Ishii A, et al: ERK1/ERK2 MAPK signaling is required to increase myelin thickness independent of oligodendrocyte differentiation and initiation of myelination. J Neurosci 2012; 32: 8855-8864.
42. Richtand NM, et al: Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 2006; 31: 77-89.
43. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press, 1998.
44. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976; 72: 248-254.
45. Cox J, et al: Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011; 10: 1794-1805.
46. Luber CA, et al: Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 2010; 32: 279-289.
47. Cox J, Mann M: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26: 1367-1372.
48. De Godoy LM, et al: Comprehensive massspectrometry-based proteome quantification of haploid versus diploid yeast. Nature 2008; 455: 1251-1254.
49. Callister SJ, et al: Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 2006; 5: 277-286.
50. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57: 289-300.
51. Martins-de-Souza D, et al: Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 2009; 116: 275-289.
52. Moens U, Kostenko S, Sveinbjornsson B: The role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes 2013; 4: 101-133.
53. Farrelly LA, et al: Adolescent risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex. Proteomics 2014; 14: 1574-1578.
54. Pacheco-Lopez G, et al: Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr Bull 2013; 39: 319-329.
55. Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 2012; 26(suppl):33-41.
56. Palacios-Callender M, et al: Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc Natl Acad Sci USA 2004; 101: 7630-7635.
57. Schwarz KB: Oxidative stress during viral infection: a review. Free Radic Biol Med 1996; 21: 641-649.
58. Maurer I, Zierz S, Moller H: Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 2001; 48: 125-136.
59. Ben-Shachar D, Karry R: Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PloS One 2008; 3:e3676.
60. Bubber P, et al: Mitochondrial enzymes in schizophrenia. J Mol Neurosci 2004; 24: 315-321.
61. Cai HL, et al: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 2012; 11: 4338-4350.
62. Ortiz E, et al: Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res 2004; 77: 681-689.
63. Beltran-Navarro B, et al: Effect of chronic iron deficiency on neuropsychological domains in infants. J Child Neurol 2012; 27: 297-303.
64. McGrath J, Brown A, St Clair D: Prevention and schizophrenia-the role of dietary factors. Schizophr Bull 2011; 37: 272-283.
65. Brown AS, Susser ES: Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull 2008; 34: 1054-1063.
66. Todorich B, Zhang X, Connor JR: H-ferritin is the major source of iron for oligodendrocytes. Glia 2011; 59: 927-935.
67. Schubert KO, et al: Hypothesis review: are clathrin-mediated endocytosis and clathrindependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 2012; 17: 669-681.
68. Gurgis FM, Ziaziaris W, Munoz L: Mitogenactivated protein kinase-activated protein kinase in neuroinflammation, heat shock protein phosphorylation, and cell cycle: role and targeting. Mol Pharmacol 2014; 85: 345-356.
69. Kyriakis JM, Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737.
70. Kaminska B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754: 253-262.
71. Kyriakis JM, Avruch J: Mammalian mitogenactivated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-869.
72. Hogg S: A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 1996; 54: 21-30.
73. Leysen JE, et al: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55(suppl):5-12.
74. Bsibsi M, et al: Toll-like receptors 2 and 3 agonists differentially affect oligodendrocyte survival, differentiation, and myelin membrane formation. J Neurosci Res 2012; 90: 388-398.
75. Girgis RR, Kumar SS, Brown AS: The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014; 75: 292-299.